Company: DARE
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001401914-25-000044
Chunk: 23

Company: Dare Bioscience, Inc.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 1
Chunk 23
---
 assets29,070 14,148 Operating lease liability(266,338)(237,949)Accounts payable(152,082)(1,475,791)Accrued expenses(388,070)(1,367,460)Interest payable268,738 247,520 Deferred grant funding(4,234,748)(2,799,491)Net cash (used in) provided by operating activities(10,887,999)6,091,723 Cash flows from investing activitiesPurchases of property and equipment(3,935)(292,522)Net cash used in investing activities(3,935)(292,522)Cash flows from financing activitiesNet proceeds from issuance of common stock 911,261 398,091 Repayment of liability on sale of future royalties— (1,505)Principal payments on financing lease(458,850)— Payments on note payable(249,628)(267,188)Net cash provided by financing activities202,783 129,398 Effect of exchange rate changes on cash and cash equivalents and restricted cash 25,983 (24,663)Net change in cash, cash equivalents and restricted cash(10,663,168)5,903,936 Cash, cash equivalents, and restricted cash,  beginning of period15,998,174 10,811,056 Cash, cash equivalents, and restricted cash, end of period$5,335,006 $16,714,992 Reconciliation of cash, cash equivalents and restricted cash to amounts reported in the condensed consolidated balance sheets:Cash and cash equivalents$5,035,006 16,414,992 Restricted cash included in other non-current assets300,000 300,000 Total cash, cash equivalents and restricted cash$5,335,006 $16,714,992 Supplemental disclosure of non-cash investing and financing activities:Operating right-of-use assets obtained in exchange for new operating lease liabilities, net$— $358,315 Finance right-of-use asset obtained in exchange for new finance lease liability$2,841,027 $— Prepaid rent reclassified to finance lease right-of-use asset$458,850 $— Finance lease payment due included in accounts payable$458,850 $— Additions to property and equipment included in accrued expenses$330,196 $— 

See accompanying notes.

5

Daré Bioscience, Inc. and Subsidi